DERMATA THERAPEUTICS INC (DRMA) Stock Price & Overview

NASDAQ:DRMA • US2498455045

1.21 USD
+0.03 (+2.54%)
At close: Mar 5, 2026
1.1769 USD
-0.03 (-2.74%)
Pre-Market: 3/6/2026, 8:44:29 AM

The current stock price of DRMA is 1.21 USD. Today DRMA is up by 2.54%. In the past month the price decreased by -37.31%. In the past year, price decreased by -90%.

DRMA Key Statistics

52-Week Range1.11 - 23.7
Current DRMA stock price positioned within its 52-week range.
1-Month Range1.11 - 2.29
Current DRMA stock price positioned within its 1-month range.
Market Cap
2.892M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-28.41
Dividend Yield
N/A

DRMA Stock Performance

Today
+2.54%
1 Week
-3.20%
1 Month
-37.31%
3 Months
-56.79%
Longer-term
6 Months -76.98%
1 Year -90.00%
2 Years -98.04%
3 Years -99.37%
5 Years N/A
10 Years N/A

DRMA Stock Chart

DERMATA THERAPEUTICS INC / DRMA Daily stock chart

DRMA Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to DRMA. When comparing the yearly performance of all stocks, DRMA is a bad performer in the overall market: 98.34% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
DRMA Full Technical Analysis Report

DRMA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to DRMA. DRMA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
DRMA Full Fundamental Analysis Report

DRMA Earnings

Next Earnings DateMar 17, 2026
Last Earnings DateNov 14, 2025
PeriodQ3 / 2025
EPS Reported-$1.65
Revenue Reported
EPS Surprise -1.74%
Revenue Surprise %
DRMA Earnings History

DRMA Forecast & Estimates

7 analysts have analysed DRMA and the average price target is 10.2 USD. This implies a price increase of 742.98% is expected in the next year compared to the current price of 1.21.


Analysts
Analysts82.86
Price Target10.2 (742.98%)
EPS Next Y94.68%
Revenue Next YearN/A
DRMA Forecast & Estimates

DRMA Groups

Sector & Classification

DRMA Financial Highlights

Over the last trailing twelve months DRMA reported a non-GAAP Earnings per Share(EPS) of -28.41. The EPS increased by 82.7% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-8.85M
Industry RankSector Rank
PM (TTM) N/A
ROA -174.46%
ROE -223.42%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%91.91%
Sales Q2Q%N/A
EPS 1Y (TTM)82.7%
Revenue 1Y (TTM)N/A
DRMA financials

DRMA Ownership

Ownership
Inst Owners8.99%
Shares2.39M
Float1.31M
Ins Owners3.5%
Short Float %2.46%
Short Ratio0.01
DRMA Ownership

DRMA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC16410.651B
AMGN AMGEN INC16.31197.945B
GILD GILEAD SCIENCES INC16.27180.072B
VRTX VERTEX PHARMACEUTICALS INC22.6116.919B
REGN REGENERON PHARMACEUTICALS16.4780.868B
ALNY ALNYLAM PHARMACEUTICALS INC47.8442.343B
INSM INSMED INC N/A30.619B
NTRA NATERA INC N/A27.941B
BIIB BIOGEN INC12.3627.603B
UTHR UNITED THERAPEUTICS CORP16.2421.26B
MRNA MODERNA INC N/A21.03B
RVMD REVOLUTION MEDICINES INC N/A19.746B
EXAS EXACT SCIENCES CORP308.8219.715B

About DRMA

Company Profile

DRMA logo image Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2021-08-13. The firm is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.

Company Info

DERMATA THERAPEUTICS INC

3525 Del Mar Heights Rd., #322

San Diego CALIFORNIA US

CEO: Gerald T. Proehl

Employees: 8

DRMA Company Website

DRMA Investor Relations

Phone: 18582230882

DERMATA THERAPEUTICS INC / DRMA FAQ

What does DERMATA THERAPEUTICS INC do?

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2021-08-13. The firm is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.


What is the current price of DRMA stock?

The current stock price of DRMA is 1.21 USD. The price increased by 2.54% in the last trading session.


What is the dividend status of DERMATA THERAPEUTICS INC?

DRMA does not pay a dividend.


What is the ChartMill technical and fundamental rating of DRMA stock?

DRMA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the employee count for DRMA stock?

DERMATA THERAPEUTICS INC (DRMA) currently has 8 employees.


Can you provide the ownership details for DRMA stock?

You can find the ownership structure of DERMATA THERAPEUTICS INC (DRMA) on the Ownership tab.